PMID- 19758232
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20090917
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1173
DP  - 2009 Sep
TI  - In vitro effects of antiphospholipid syndrome-IgG fractions and human monoclonal 
      antiphospholipid IgG antibody on human umbilical vein endothelial cells and 
      monocytes.
PG  - 805-13
LID - 10.1111/j.1749-6632.2009.04632.x [doi]
AB  - It has been shown that stimulation of endothelial cells and monocytes by 
      antiphospholipid antibodies leads to a prothrombotic state involving upregulation 
      of tissue factor (TF). We examined the in vitro effects of IgG fractions from 
      patients with antiphospholipid syndrome (APS) and of a beta-2-glycoprotein 
      1-independent human monoclonal antiphospholipid antibody (HL-5B) on human 
      umbilical vein endothelial cells (HUVEC) in comparison to untreated cell controls 
      and to exposure to monoclonal IgG control antibody. We also examined the effect 
      of recombinant monocyte chemoattractant protein-1 (MCP-1) on peripheral blood 
      monocytes. Stimulation of endothelial cells with APS IgG fractions or HL-5B 
      resulted in time-dependent upregulation of MCP-1 mRNA and protein expression. 
      Stimulation with HL-5B also led to time-dependent upregulation of interleukin 
      (IL)-8 and intracellular adhesion molecule-1 (ICAM-1) mRNA and IL-8 protein 
      expressions. Stimulation of monocytes with recombinant MCP-1 resulted in an 
      upregulation of TF mRNA and TF protein. In conclusion these results might 
      represent a mechanism for antiphospholipid antibody-mediated thrombosis in APS 
      patients.
FAU - Clemens, Natascha
AU  - Clemens N
AD  - Institut fur Klinische Chemie und Laboratoriumsmedizin, Universitatsmedizin der 
      Johannes Gutenberg-Universitat Mainz, Mainz, Germany.
FAU - Frauenknecht, Katrin
AU  - Frauenknecht K
FAU - Katzav, Aviva
AU  - Katzav A
FAU - Sommer, Clemens
AU  - Sommer C
FAU - von Landenberg, Philipp
AU  - von Landenberg P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin-8)
RN  - 0 (RNA, Messenger)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 9035-58-9 (Thromboplastin)
SB  - IM
MH  - Antibodies, Antiphospholipid/*immunology
MH  - Antibodies, Monoclonal/immunology
MH  - Antiphospholipid Syndrome/*immunology
MH  - Cells, Cultured
MH  - Chemokine CCL2/genetics/metabolism/pharmacology
MH  - Endothelial Cells/cytology/*drug effects/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Immunoblotting
MH  - Immunoglobulin G/immunology/*pharmacology
MH  - Intercellular Adhesion Molecule-1/genetics/metabolism
MH  - Interleukin-8/genetics/metabolism
MH  - Monocytes/cytology/*drug effects/metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Thromboplastin/genetics/metabolism
MH  - Time Factors
MH  - Umbilical Veins/cytology
EDAT- 2009/09/18 06:00
MHDA- 2009/10/30 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
AID - NYAS4632 [pii]
AID - 10.1111/j.1749-6632.2009.04632.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2009 Sep;1173:805-13. doi: 10.1111/j.1749-6632.2009.04632.x.